Atara Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities | ||
| Net loss | $(276,126) | $(228,302) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Gain on sale of ATOM Facility | — | (50,237) |
| Stock-based compensation expense | 45,386 | 53,838 |
| Depreciation and amortization expense | 4,829 | 5,653 |
| Accretion of liability related to sale of future revenues | 4,792 | — |
| Non-cash operating lease expense | 11,795 | 8,915 |
| Amortization of investment premiums | 792 | 1,024 |
| Other non-cash items, net | 214 | 147 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 6,113 | (39,235) |
| Inventories | (8,120) | (1,586) |
| Other current assets | 273 | 1,836 |
| Other assets | 1,043 | (266) |
| Accounts payable | (3,130) | (9,211) |
| Accrued compensation | (6,140) | (7,491) |
| Accrued research and development expenses | (3,663) | 11,541 |
| Other current liabilities | 11,064 | 2,067 |
| Deferred revenue | 30,395 | (11,468) |
| Operating lease liabilities | (12,636) | (8,009) |
| Other long-term liabilities | 142 | 354 |
| Net cash used in operating activities | (192,977) | (270,430) |
| Investing activities | ||
| Purchases of short-term investments | (83,648) | (180,589) |
| Proceeds from maturities and sales of short-term investments | 208,712 | 292,973 |
| Purchases of property and equipment | (1,223) | (4,193) |
| Proceeds from sale of property and equipment | 25 | — |
| Net proceeds from sale of ATOM Facility | — | 94,765 |
| Net cash provided by (used in) investing activities | 123,866 | 202,956 |
| Financing activities | ||
| Proceeds from issuance of common stock through ATM facilities, net | 2,136 | 21,891 |
| Proceeds from employee stock awards | 928 | 1,921 |
| Proceeds from sale of future revenues, net | — | 30,605 |
| Taxes paid related to net share settlement of restricted stock units | (94) | (623) |
| Principal payments on finance lease obligations | (947) | (518) |
| Other financing activities, net | (13) | (192) |
| Net cash provided by financing activities | 2,010 | 53,084 |
| Increase (decrease) in cash, cash equivalents and restricted cash | (67,101) | (14,390) |
| Cash, cash equivalents and restricted cash at beginning of period | 93,088 | 107,478 |
| Cash, cash equivalents and restricted cash at end of period | $25,987 | $93,088 |
| Non-cash investing and financing activities | ||
| Property and equipment purchases included in accounts payable and other accrued liabilities | $132 | $61 |
| Accrued costs related to ATM facilities | $78 | $— |
| Proceeds from issuance of common stock through ATM facilities not yet received | $114 | $— |
| Accrued transaction costs related to sale of future revenues | $— | $332 |
| Supplemental cash flow disclosure | ||
| Cash paid for interest | $447 | $335 |
| Cash paid for income taxes | $2 | $19 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.